Lanean...
Discovery of a Small Molecule Drug Candidate for Selective NKCC1 Inhibition in Brain Disorders
Aberrant expression ratio of Cl(−) transporters, NKCC1 and KCC2, is implicated in several brain conditions. NKCC1 inhibition by the FDA-approved diuretic drug, bumetanide, rescues core symptoms in rodent models and/or clinical trials with patients. However, bumetanide has a strong diuretic effect du...
Gorde:
| Argitaratua izan da: | Chem |
|---|---|
| Egile Nagusiak: | , , , , , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Elsevier
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7427514/ https://ncbi.nlm.nih.gov/pubmed/32818158 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.chempr.2020.06.017 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|